Novartis NRT gum OTC
This article was originally published in The Tan Sheet
Executive Summary
Novartis Consumer Health plans by the end of 2007 to make available nationwide its 2 mg and 4 mg Thrive (nicotine polacrilex) nicotine-replacement therapy gum, following FDA's ANDA approval of the product for over-the-counter sales, the firm says June 21. The Parsippany, N.J.-based division of Novartis says the mint-flavored gum delivers nicotine to the bloodstream in "low, controlled levels" to help reduce cravings and other symptoms of smoking cessation. The 2 mg product is designed for users who smoke fewer than 25 cigarettes a day and the 4 mg version is for people with a daily habit of at least 25 cigarettes. The firm says the 12-week program printed on the user's guide in Thrive packages and available on a CD will help consumers reduce their nicotine levels and quit smoking. Novartis also will operate a toll-free phone service to counsel consumers, citing the American Legacy Foundation's guidance to combine nicotine replacement therapy with counseling and social support as part of a comprehensive plan for quitting...
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.